Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar lennysims (97.02) Submitted: 6/13/2011 12:36:48 PM : Outperform Start Price: $6.04 CRME Score: -91.49

magic formula, no additional research.

Featured Broker Partners


Advertisement